A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3
Status:
Not yet recruiting
Trial end date:
2026-01-12
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of multiple
ascending doses of BIIB132 administered via intrathecal (IT) injection to participants with
spinocerebellar ataxia type 3 (SCA3). The secondary objective of this study is to
characterize the multiple-dose pharmacokinetics (PK) of BIIB132 administered via IT injection
to participants with SCA3.